Drs Samuel Klempner and Zev Wainberg discuss standard-of-care, second-line, and future therapies for GE junction, esophageal, and gastric cancers.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999883. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Esophageal Cancer https://emedicine.medscape.com/article/277930-overview

Scoring Systems for PD-L1 Expression and Their Prognostic Impact in Patients With Resectable Gastric Cancer https://pubmed.ncbi.nlm.nih.gov/33098489/

Assessment of Ramucirumab Plus Paclitaxel as Switch Maintenance Versus Continuation of First-Line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: The ARMANI Phase III Trial https://pubmed.ncbi.nlm.nih.gov/30922323/

Clinical Circulating Tumor DNA Testing for Precision Oncology https://pubmed.ncbi.nlm.nih.gov/36915242/

Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade https://pubmed.ncbi.nlm.nih.gov/35649217/

The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer https://pubmed.ncbi.nlm.nih.gov/34912120/

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) https://clinicaltrials.gov/study/NCT04704934

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape https://pubmed.ncbi.nlm.nih.gov/36831367/

An Introduction to the Performance of Immunohistochemistry https://pubmed.ncbi.nlm.nih.gov/30539453/

Anti-TIGIT Therapies for Solid Tumors: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/36933320/

LAG-3 as the Third Checkpoint Inhibitor https://pubmed.ncbi.nlm.nih.gov/37488429/

Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells https://pubmed.ncbi.nlm.nih.gov/38587317/

Fruquintinib Plus Paclitaxel Versus Paclitaxel as Second-Line Therapy for Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (FRUTIGA): A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study https://ascopubs.org/doi/10.1200/JCO.2024.42.36_suppl.438780

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/36238135/

Bemarituzumab in Patients With FGFR2b-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FIGHT): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/36244398/

Optimism Surrounds Claudin 18.2 ADC https://pubmed.ncbi.nlm.nih.gov/37975577/

Methionine Adenosyltransferases in Cancers: Mechanisms of Dysregulation and Implications for Therapy https://pubmed.ncbi.nlm.nih.gov/29141455/